Clinical data | |
---|---|
Trade names | Stribild (fixed-dose combination) |
Routes of administration | oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 98% |
Metabolism | liver, via CYP3A |
Elimination half-life | 12.9 hours |
Excretion | liver 93%, renal 7% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
Chemical and physical data | |
Formula | C23H23ClFNO5 |
Molar mass | 447.883 g/mol g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Elvitegravir (EVG, formerly GS-9137) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed [1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. [2] [3] [4] The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. [5] On September 24, 2014 the FDA approved Elvitegravir (tradename Vitekta) as a single pill formulation. [6]
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor. [7]
In the United States, elvitegravir can be obtained either as part of the combination pill Stribild or as the single pill formulation Vitekta. [8]
Vitekta is FDA approved to be used for the treatment of HIV-1 infection in adults who have previous treatment experience with antiretroviral therapy. It must be used in combination with a protease inhibitor that is coadministered with ritonavir as well as additional antiretroviral drug(s). [9]
According to the package insert, the most common side effect of taking Vitekta is diarrhea. [9]
{{
cite journal}}
: Explicit use of et al. in: |author=
(
help)CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
Category:Integrase inhibitors Category:Quinolines Category:Organochlorides Category:Organofluorides Category:Japan Tobacco
Clinical data | |
---|---|
Trade names | Stribild (fixed-dose combination) |
Routes of administration | oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 98% |
Metabolism | liver, via CYP3A |
Elimination half-life | 12.9 hours |
Excretion | liver 93%, renal 7% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
Chemical and physical data | |
Formula | C23H23ClFNO5 |
Molar mass | 447.883 g/mol g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Elvitegravir (EVG, formerly GS-9137) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed [1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. [2] [3] [4] The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. [5] On September 24, 2014 the FDA approved Elvitegravir (tradename Vitekta) as a single pill formulation. [6]
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor. [7]
In the United States, elvitegravir can be obtained either as part of the combination pill Stribild or as the single pill formulation Vitekta. [8]
Vitekta is FDA approved to be used for the treatment of HIV-1 infection in adults who have previous treatment experience with antiretroviral therapy. It must be used in combination with a protease inhibitor that is coadministered with ritonavir as well as additional antiretroviral drug(s). [9]
According to the package insert, the most common side effect of taking Vitekta is diarrhea. [9]
{{
cite journal}}
: Explicit use of et al. in: |author=
(
help)CS1 maint: multiple names: authors list (
link)
{{
cite journal}}
: CS1 maint: numeric names: authors list (
link)
Category:Integrase inhibitors Category:Quinolines Category:Organochlorides Category:Organofluorides Category:Japan Tobacco